%0 Case Reports
%T EGFR-TKI-induced Factor V deficiency in a patient with advanced non-small cell lung cancer: The first case report.
%A Yoshizaki C
%A Yoshida Y
%A Nohmi S
%A Go Y
%A Kusakado R
%A Kawamura S
%A Inoue D
%A Kabasawa N
%A Yamaguchi F
%J Lung Cancer
%V 194
%N 0
%D 2024 Aug 1
%M 38970909
%F 6.081
%R 10.1016/j.lungcan.2024.107869
%X Osimertinib, a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), is routinely prescribed as first-line therapy for advanced non-small cell lung cancer, regardless of the presence of the T790M resistance mutation. This study reports a rare case of Factor V inhibitor detection during osimertinib therapy in a patient with lung adenocarcinoma. These findings underscore the importance of vigilant monitoring for coagulation abnormalities during EGFR-TKI therapy.